Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients – American College of Cardiology
Dharam J. Kumbhani, MD, SM, FACC
Related Articles
Blood test can predict women’s risk for cardiovascular disease in 30 years, study says – UPI.com
A single blood test measuring inflammation and fat can predict a women’s risk for cardiovascular disease 30 years later, a new study suggests.
The Best Cardiology Hospitals in America
Learn which hospitals were ranked best by US News & World Report for treating cardiology & heart surgery. Scores factor in patient safety, nurse staffing…
Coronary Artery Bypass Graft Failure in Women: Incidence and Clinical Implications
AbstractBackgroundWomen have worse outcomes after coronary artery bypass surgery (CABG) than men.ObjectivesThis study aimed to determine the incidence of CABG graft failure in women, its…
Which Test Should I Order for an Inpatient Evaluation of Cardiac Ischemia?
Testing for cardiac ischemia, or for the obstructive coronary artery disease (CAD) that causes cardiac ischemia, is common among hospitalized patients. Many testing options exist.…
Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF:
AbstractBackgroundThe efficacy of sotagliflozin in patients with diabetes and recent worsening of heart failure was shown in the SOLOIST-WHF trial. However, the cost-effectiveness of sotagliflozin…
Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF:
AbstractBackgroundThe efficacy of sotagliflozin in patients with diabetes and recent worsening of heart failure was shown in the SOLOIST-WHF trial. However, the cost-effectiveness of sotagliflozin…
New York, London Top New Ranking of 1,000 Global Cities
Cities in the US and Europe dominated the top 50, based on factors ranging from economic output to quality of life.
Evaluating Safety of Novel LDL Management Mechanism
Deepak Bhatt, MD, MPH, MBA, reviews the efficacy and safety data of inclisiran, highlighting its long-term effects and noting that injection site reactions are among…
Evaluating Safety of Novel LDL Management Mechanism
Deepak Bhatt, MD, MPH, MBA, reviews the efficacy and safety data of inclisiran, highlighting its long-term effects and noting that injection site reactions are among…
Weekly journal scan: the KCa2 potassium channel as a promising target for the pharmacologic cardioversion of atrial fibrillation
Comment on the article ‘Inhibition of the KCa2 potassium channel in atrial fibrillation: a randomized phase 2 trial’, which was published in Nature Med; ht